Masanori Kitamura
Papers
1
Total Citations
13
H-Index
1
About
Masanori Kitamura is a clinical researcher whose work focuses on the intersection of advanced gastric cancer therapeutics and real-world adverse event monitoring. His most notable contribution comes from a 2025 case report documenting two instances of protein-losing enteropathy induced by zolbetuximab in patients with unresectable advanced gastric cancer. This work is critically important because, while the landmark GLOW and SPOTLIGHT trials established the efficacy of combining chemotherapy with zolbetuximab for HER2-negative, CLDN18.2-positive disease, Kitamura’s report provides the first detailed clinical evidence of a serious, previously underrecognized toxicity in a real-world setting. Garnering 13 citations in a short period, this paper has already become a key reference for oncologists balancing the drug’s survival benefits against its gastrointestinal risks. Kitamura’s research thus bridges the gap between controlled trial data and clinical practice, offering essential safety insights that inform treatment decisions for advanced gastric cancer patients. His work underscores the vital role of post-marketing surveillance in refining targeted therapies.
Research Focus
Key Achievements
Top Papers
- 1